COVID-19 Information
Phase III clinical trial to evaluate lenzilumab for the prevention and treatment of cytokine storm arising from COVID-19.
- Lenzilumab neutralizes granulocyte macrophage colony stimulating factor (GM-CSF) a key cytokine in the initiation of cytokine storm
- GM-CSF is up-stream of interleukin-6 (IL-6) in the development of cytokine storm
- GM-CSF is up-regulated in COVID-19 patients and may cause a harmful immune response, which contributes to cytokine storm in patients at risk of developing acute respiratory distress syndrome (ARDS)
FDA Approves Emergency IND Use of Humanigen’s Lenzilumab for Compassionate Use in COVID-19 Patients
Lenzilumab for Compassionate Use - Humanigen is now accepting enquiries regarding lenzilumab for compassionate use.
Stage
Phase 3
Expanded Access
Company Type
Late Onset Intervention